176 related articles for article (PubMed ID: 2143859)
1. Prolonged and repeated courses of OKT3 after liver transplantation.
Colledan M; Gridelli B; Rossi G; Caccamo L; Gatti S; Bonara P; Fassati LR; Ferla G; Maggi U; Reggiani P
Transplant Proc; 1990 Aug; 22(4):1769-71. PubMed ID: 2143859
[No Abstract] [Full Text] [Related]
2. The successful use of repeated courses of OKT3 for hepatic allograft rejection using %T3 cells to adjust dose.
Colonna JO; Millis JM; Martello J; Levy P; Iwaki Y; Brems JJ; Klein AS; Hiatt JR; Busuttil RW
Transplant Proc; 1989 Feb; 21(1 Pt 2):2247-8. PubMed ID: 2523600
[No Abstract] [Full Text] [Related]
3. OKT3 resistant rejection in liver transplant patients.
Sutherland F; Lazarovits A; Aboujaoude M; Grant D; Ghent C; Sommerauer J; Wall W
Transplant Proc; 1991 Feb; 23(1 Pt 2):1413-4. PubMed ID: 1824898
[No Abstract] [Full Text] [Related]
4. In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment.
Caillat-Zucman S; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
Transplant Proc; 1990 Aug; 22(4):1782. PubMed ID: 2143860
[No Abstract] [Full Text] [Related]
5. Experience with OKT3 after orthotopic liver transplantation.
Stratta R; Shaefer M; Bradshaw K; Wood R; Langnas A; Zetterman R; Donovan J; Sorrell M; Markin R; Shaw BW
Transplant Proc; 1991 Jun; 23(3):1970. PubMed ID: 1829556
[No Abstract] [Full Text] [Related]
6. Use of OKT3 in kidney, pancreas, and liver transplantation.
D'Alessandro AM; Pirsch JD; Melzer JS; Sollinger HW; Kalayoglu M; Reed A; Knechtle SJ; Belzer FO
Transplant Proc; 1990 Aug; 22(4):1748-9. PubMed ID: 2117796
[No Abstract] [Full Text] [Related]
7. Immunologic monitoring with Orthoclone OKT3 therapy.
Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
[TBL] [Abstract][Full Text] [Related]
8. Effect of the HLA-DRw6 antigen in liver transplantation.
Saito S; Stratta RJ; Grazi GL; Castaldo P; Langnas AN; Wood RP; Shaw BW
Transplant Proc; 1991 Feb; 23(1 Pt 2):1430-1. PubMed ID: 1824899
[No Abstract] [Full Text] [Related]
9. In vivo-in vitro correlates of human rejection using flow cytometry with two-color fluorescence on peripheral blood mononuclear cells.
Gross U; Thomas F; Matthews C; Thomas J; Cunningham P; Ritter T
Transplant Proc; 1987 Feb; 19(1 Pt 2):1609-10. PubMed ID: 2978885
[No Abstract] [Full Text] [Related]
10. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
[No Abstract] [Full Text] [Related]
11. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients.
Renard TH; Andrews WS; Foster ME
Transplant Proc; 1991 Feb; 23(1 Pt 2):1473-6. PubMed ID: 1846468
[No Abstract] [Full Text] [Related]
12. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation.
Knechtle SJ; Pirsch JD; Groshek M; Reed A; D'Alessandro AM; Kalayoglu M; Belzer FO; Sollinger HW
Transplant Proc; 1991 Feb; 23(1 Pt 2):1581-2. PubMed ID: 1846478
[No Abstract] [Full Text] [Related]
13. Clinical development of Orthoclone OKT3.
Cosimi AB
Transplant Proc; 1987 Apr; 19(2 Suppl 1):7-16. PubMed ID: 3105142
[No Abstract] [Full Text] [Related]
14. OKT3 therapy for hepatic allograft rejection: comparison of results in adults and children.
Woodle ES; Thistlethwaite JR; Emond JC; Whitington PF; Black DD; Aran PP; Baker AL; Stuart FP; Broelsch CE
Transplant Proc; 1990 Aug; 22(4):1765-6. PubMed ID: 2117803
[No Abstract] [Full Text] [Related]
15. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies.
Henell KR; Bakke A; Kenny TA; Kimball JA; Barry JM; Norman DJ
Transplant Proc; 1991 Feb; 23(1 Pt 2):1070-1. PubMed ID: 1824886
[No Abstract] [Full Text] [Related]
16. Nashville antithymocyte serum: a safe and efficacious agent for prophylaxis after heart transplantation.
Frist WH; Merrill WH; Eastburn TE; Stewart JR; Hammon JW; Fortune DS; Guy TS; Bender HW
Transplant Proc; 1991 Feb; 23(1 Pt 2):1160-1. PubMed ID: 1846455
[No Abstract] [Full Text] [Related]
17. Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation.
Broughan TA; Valenzuela R; Escorcia E; Secic M; Vogt DP
Clin Transplant; 1994 Oct; 8(5):488-91. PubMed ID: 7819617
[TBL] [Abstract][Full Text] [Related]
18. Are OKT3 binding sites on T cells modulated or merely converted (blindfolded) by OKT3 during therapy?
Carreno M; Miller J; Esquenazi V; Milgrom M; Roth D; Fuller L
Transplant Proc; 1989 Feb; 21(1 Pt 1):987-8. PubMed ID: 2565060
[No Abstract] [Full Text] [Related]
19. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
Goldstein G
Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
[No Abstract] [Full Text] [Related]
20. Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation.
Steininger R; Mühlbacher F; Hamilton G; Längle F; Gnant M; Popow T; Sautner T; Götzinger P; Wamser P; Stockenhuber F
Transplant Proc; 1991 Aug; 23(4):2269-71. PubMed ID: 1908154
[No Abstract] [Full Text] [Related]
[Next] [New Search]
